August 12, 2024, OPTITHERA obtained and Investigational testing authorization for medical devices from Health Canada, to sell its test for investigational testing to the investigators of the clinical study entitled: New Genomic predictor for complication risk in type 2 diabetes (GENOCORDIA).

The objective of the study is to provide Real World Evidence (RWE) on the impact of the result transmission of a PRS prediction test on the risk of cardiorenal complications of T2D, so that more patients a high risk of cardiorenal complications approach/achieve, over an 18-month period, recommended targets for systolic blood pressure, glycated hemoglobin or decreased albuminuria grade while avoiding severe hypoglycemia and falls.